Helen Y Hougen1, Oleksii A Iakymenko2, Sanoj Punnen3,4,5, Chad R Ritch3,4,5, Bruno Nahar3,4,5, Dipen J Parekh3,4,5, Oleksandr N Kryvenko3,2,4,5, Mark L Gonzalgo3,4,5. 1. Desai Sethi Urology Institute, University of Miami Miller School of Medicine, 1120 NW 14th Street, CRB 15th Floor, Miami, FL, 33136, USA. hhougen@med.miami.edu. 2. Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 3. Desai Sethi Urology Institute, University of Miami Miller School of Medicine, 1120 NW 14th Street, CRB 15th Floor, Miami, FL, 33136, USA. 4. Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. 5. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract
PURPOSE: Radical prostatectomy (RP) outcomes in Hispanic men with prostate cancer are not well-described. Prior studies showed varying results regarding the rate of upgrading and upstaging, and these studies included limited pathologic data and lack of central pathology review. We characterized the rate of upgrading, adverse pathology, and oncologic outcomes in Hispanics after prostatectomy using a large institutional database. METHODS: We included Hispanic white (HW), non-Hispanic white (NHW), and black men who underwent (RP) between 2010 and 2021 at a single institution. We recorded differences in grade group between biopsy and prostatectomy and performed multivariable analyses for odds of upgrading and adverse pathologic findings. The primary outcome was rate of upgrading in HWs. Using a sub-cohort with follow-up data, we assessed race/ethnicity and upgrading as a predictor of biochemical recurrence (BCR)-free survival. RESULTS: Our cohort included 1877 men: 36.7% were NHW, 40.6% were HW, and 22.7% were black. Rates of upgrading were not different between NHW, NHW, and black men at 34.0, 33.8, and 37.3%, respectively (p = 0.4). In the multivariable analysis for upgrading, significant predictors for upgrading were older age (p = 0.002), higher PSA (p < 0.001), and lower prostate weight (p = 0.02), but race/ethnicity did not predict upgrading. In patients with available follow-up (1083, 58%), upgrading predicted worse BCR-free survival (HR 2.17, CI 1.46-3.22, p < 0.0001) but race/ethnicity did not. CONCLUSIONS: HW men undergoing RP had similar rates of upgrading and adverse pathologic outcomes as NHW men. Race/ethnicity does not independently predict upgrading or worse oncologic outcomes after RP.
PURPOSE: Radical prostatectomy (RP) outcomes in Hispanic men with prostate cancer are not well-described. Prior studies showed varying results regarding the rate of upgrading and upstaging, and these studies included limited pathologic data and lack of central pathology review. We characterized the rate of upgrading, adverse pathology, and oncologic outcomes in Hispanics after prostatectomy using a large institutional database. METHODS: We included Hispanic white (HW), non-Hispanic white (NHW), and black men who underwent (RP) between 2010 and 2021 at a single institution. We recorded differences in grade group between biopsy and prostatectomy and performed multivariable analyses for odds of upgrading and adverse pathologic findings. The primary outcome was rate of upgrading in HWs. Using a sub-cohort with follow-up data, we assessed race/ethnicity and upgrading as a predictor of biochemical recurrence (BCR)-free survival. RESULTS: Our cohort included 1877 men: 36.7% were NHW, 40.6% were HW, and 22.7% were black. Rates of upgrading were not different between NHW, NHW, and black men at 34.0, 33.8, and 37.3%, respectively (p = 0.4). In the multivariable analysis for upgrading, significant predictors for upgrading were older age (p = 0.002), higher PSA (p < 0.001), and lower prostate weight (p = 0.02), but race/ethnicity did not predict upgrading. In patients with available follow-up (1083, 58%), upgrading predicted worse BCR-free survival (HR 2.17, CI 1.46-3.22, p < 0.0001) but race/ethnicity did not. CONCLUSIONS: HW men undergoing RP had similar rates of upgrading and adverse pathologic outcomes as NHW men. Race/ethnicity does not independently predict upgrading or worse oncologic outcomes after RP.
Authors: Jonathan E Katz; Felix M Chinea; Vivek N Patel; Raymond R Balise; Vivek Venkatramani; Mark L Gonzalgo; Chad Ritch; Alan Pollack; Dipen J Parekh; Sanoj Punnen Journal: Prostate Cancer Prostatic Dis Date: 2018-07-09 Impact factor: 5.554
Authors: Luigi Nocera; Mike Wenzel; Claudia Collà Ruvolo; Christoph Würnschimmel; Zhe Tian; Giorgio Gandaglia; Nicola Fossati; Felix K H Chun; Vincenzo Mirone; Markus Graefen; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2021-08-26 Impact factor: 4.226
Authors: Denzel Zhu; William Shyr; Michelle Toker; Ethan Fram; Jinrong Cheng; Evan Z Kovac; Ilir Agalliu; Ahmed Aboumohamed; Kara L Watts Journal: World J Urol Date: 2021-11-30 Impact factor: 4.226
Authors: Maureen R Benjamins; Bijou R Hunt; Sarah M Raleigh; Jana L Hirschtick; Michelle M Hughes Journal: Cancer Epidemiol Date: 2016-08-24 Impact factor: 2.984
Authors: Marianne Schmid; Christian P Meyer; Gally Reznor; Toni K Choueiri; Julian Hanske; Jesse D Sammon; Firas Abdollah; Felix K H Chun; Adam S Kibel; Reginald D Tucker-Seeley; Philip W Kantoff; Stuart R Lipsitz; Mani Menon; Paul L Nguyen; Quoc-Dien Trinh Journal: JAMA Oncol Date: 2016-01 Impact factor: 31.777
Authors: John S Lam; Joshua D Sclar; Manisha Desai; Mahesh M Mansukhani; Mitchell C Benson; Erik T Goluboff Journal: J Urol Date: 2004-11 Impact factor: 7.450
Authors: Lourdes Guerrios-Rivera; Lauren E Howard; Zachary Klaassen; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; William J Aronson; Stephen J Freedland Journal: Urology Date: 2020-11-12 Impact factor: 2.649
Authors: Felix M Chinea; Vivek N Patel; Deukwoo Kwon; Narottam Lamichhane; Chris Lopez; Sanoj Punnen; Erin N Kobetz; Matthew C Abramowitz; Alan Pollack Journal: Oncotarget Date: 2017-07-06